Your browser doesn't support javascript.
loading
Evaluation of acute myeloid leukemia blast percentage on MethylC-Capture Sequencing results.
Yang, Erna; Gong, Desheng; Guan, Wei; Li, Jieying; Gao, Xuefeng; Li, Yonghui; Yu, Li.
Afiliación
  • Yang E; Department of Hematology and Oncology, International Cancer Center, Shenzhen Key Laboratory of Precision Medicine for Hematological Malignancies, Shenzhen University General Hospital, Shenzhen University Clinical Medical Academy, Shenzhen University Health Science Center, Shenzhen University, Xueyua
  • Gong D; Department of Hematology and Oncology, International Cancer Center, Shenzhen Key Laboratory of Precision Medicine for Hematological Malignancies, Shenzhen University General Hospital, Shenzhen University Clinical Medical Academy, Shenzhen University Health Science Center, Shenzhen University, Xueyua
  • Guan W; Department of Hematology, Chinese PLA General Hospital, Beijing, 100853, China.
  • Li J; Department of Hematology and Oncology, International Cancer Center, Shenzhen Key Laboratory of Precision Medicine for Hematological Malignancies, Shenzhen University General Hospital, Shenzhen University Clinical Medical Academy, Shenzhen University Health Science Center, Shenzhen University, Xueyua
  • Gao X; Centrol Laboratory, Shenzhen University General Hospital, Shenzhen University Health Science Center, Xueyuan AVE 1098, Nanshan District, Shenzhen, Guangdong, 518000, People's Republic of China. xfgao@szu.edu.cn.
  • Li Y; Centrol Laboratory, Shenzhen University General Hospital, Shenzhen University Health Science Center, Xueyuan AVE 1098, Nanshan District, Shenzhen, Guangdong, 518000, People's Republic of China. yonghuili@szu.edu.cn.
  • Yu L; Department of Hematology and Oncology, International Cancer Center, Shenzhen Key Laboratory of Precision Medicine for Hematological Malignancies, Shenzhen University General Hospital, Shenzhen University Clinical Medical Academy, Shenzhen University Health Science Center, Shenzhen University, Xueyua
Exp Hematol Oncol ; 10(1): 26, 2021 Mar 31.
Article en En | MEDLINE | ID: mdl-33789763
ABSTRACT
Aberrant DNA methylation is often related to the diagnosis, prognosis, and therapeutic response of acute myeloid leukemia (AML); however, relevant studies on the relationship between bone marrow myeloblast percentage and the DNA methylation level in AML have not been reported. We evaluated the effects of AML blast percentage on DNA methylation level using the MethylC-capture sequencing (MCC-Seq) approach based on next-generation sequencing (NGS) and found that the methylation level of both genome-wide and promoter regions significantly increased when the percentage of AML blasts reached ≥ 40%, indicating that an accurate DNA methylation level in cancer cells can be obtained when the bone marrow samples of AML patients have more than 40% myeloblasts.
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Idioma: En Revista: Exp Hematol Oncol Año: 2021 Tipo del documento: Article

Texto completo: 1 Bases de datos: MEDLINE Idioma: En Revista: Exp Hematol Oncol Año: 2021 Tipo del documento: Article